Celularity Inc. (NASDAQ:CELUW – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 6,300 shares, a decrease of 12.5% from the January 15th total of 7,200 shares. Based on an average daily volume of 14,600 shares, the short-interest ratio is currently 0.4 days.
Celularity Price Performance
Celularity stock remained flat at $0.10 during trading hours on Friday. Celularity has a 12-month low of $0.06 and a 12-month high of $1.99.
Get Celularity alerts:Celularity Company Profile
(Get Rating)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Further Reading
- Get a free copy of the StockNews.com research report on Celularity (CELUW)
- Deere Stock Raises Outlook and is Ready to Power Higher
- DraftKings Crowning Achievement: Leverage
- Tesla Stock Comeback Is Picking Up Steam
- How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
- 3 Top-Performing Energy MLPs Deliver Price Gains, High Yield
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.